NCT01415674View on ClinicalTrials.gov

Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
DRUG

Afatinib

Afatinib 40mg per os daily for 14 to 28 days, depending on the date of the surgery

Trial Locations (11)

14000

Centre François Baclesse, Caen

31052

Institut Claudius Regaud, Toulouse

54511

Centre Alexis Vautrin, Vandœuvre-lès-Nancy

69373

Centre Léon Bérard, Lyon

75248

Institut Curie, Paris

94800

Institut Gustave Roussy, Villejuif

Unknown

CHU d'Angers, Angers

Institut de cancérologie de l'Ouest - Site Paul Papin, Angers

Chu de Nantes, Nantes

Institut de cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain

06189

Centre Antoine Lacassagne, Nice

All Listed Sponsors
lead

UNICANCER

OTHER

NCT01415674 - Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients | Biotech Hunter | Biotech Hunter